Left ventricular dysfunction and NT-proBNP levels in patients with one-vessel disease after first ST-elevation myocardial infarction treated with primary coronary angioplasty

Kardiologia Polska

Volumn 67, Issue 11, 2009, Pages 1201-1206

  Szadkowska, Iwona ^a   Pawlicki, Lucjan ^a   Kowalski, Jan ^a   Banach, Maciej ^a   Goch, Jan H ^a   Chizyński, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Coronary disease; Heart failure; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CORONARY STENT; ECHOCARDIOGRAPHY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 74849084946     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-47.
2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
3. Nunn CM, O'Neill WW, Rothbaum D, et al. Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. J Am Coll Cardiol 1999; 33: 640-6.
4. Tsuchihashi M, Tsutsui H, Shihara M, et al. Comparison of outcomes for patients undergoing balloon angioplasty vs coronary stenting for acute myocardial infarction. Circ J 2003; 67: 369-74.
5. Mehta RH, Harjai KJ, Cox DA, et al. Comparison of coronary stenting versus conventional balloon angioplasty on five-year mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2005; 96: 901-6.
6. Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilatation and long-term prognostic implications. Circulation 2002; 106: 2351-7.
7. Giannuzzi P, Temporelli PL, Bosimini E, et al. Heterogeneity of left ventricular remodeling after acute myocardial infarction: results of the GISSI-3 Echo substudy. Am Heart J 2001; 141: 131-8.
8. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107: 2786-92.
9. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Eur J Heart Fail 2008; 10: 933-89.
10. Nagaya N, Nishikimi T, Goto Y, et al. Plasma brain natriuretic peptide is a biochemicalmarker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 1998; 135: 21-8.
11. Groenning BA, Nilsson JC, Sondergaard L, et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J 2002; 143: 923-9.
12. Galvani M, Ottani F, Oltrona L, et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004; 110: 128-34.
13. Bazzino O, Fuselli JJ, Botto F, et al. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2004; 25: 1-8.
14. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. A global utilization strategies to open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108: 275-81.
15. Richards AM, Nicholls MG, Yandle TG, et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart 1999; 81: 114-20.
16. Talwar S, Squire IB, Downie PF, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction. Correlation with left ventricular systolic dysfunction. Eur Heart J 2000; 21: 1514-21.
17. Crilley JG, Farrer M. Left ventricular remodeling and brain natriuretic peptide after first myocardial infarction. Heart 2001; 86: 638-42.
18. Ribichini F, Wijns W. Acute myocardial infarction: reperfusion treatment. Heart 2002; 88: 298-305.
19. Gadsboll N, Torp-Petersen C, Hoilud-Carlsen PF. In-hospital heart failure, first-year ventricular dilatation and 10-year survival after acute myocardial infarction. Eur J Heart Fail 2001; 3: 91-6.
20. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82-91.
21. Talwar S, Squire IB, Downie PF, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction. Correlation with left ventricular systolic dysfunction. Eur Heart J 2000; 21: 1514-21.
22. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-21.
23. Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 2004; 6: 327-33.
24. Mega J, Morrow DA, de Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI23 substudy. J Am Coll Cardiol 2004; 21: 335-9.
25. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003; 41: 1264-72.
26. Bettencourt P, Ferreira A, Pardal-Oliveira N, et al. Clinical significance of brain natriuretic peptide in patients with postmyocardial infarction. Clin Cardiol 2000; 23: 921-7.
27. Nilsson JC, Groenning BA, Nielsen G, et al. Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide. Am Heart J 2002; 143: 696-702.
28. Panteghini M, Cuccia C, Bonetti G, et al. Rapid determination of brain natriuretic peptide in patients with acute myocardial infarction. Clin Chem Lab Med 2003; 41: 164-8.
29. Cocco G, Chu D. Weight reduction decreases NT-proBNP levels in obsese coronary patients with chronic diastolic heart failure. Arch Med Sci 2007; 3: 112-6.
30. Piechota M, Banach M, Jacoń A, Rysz J. Natriuretic peptides in cardiovascular diseases. Cell Mol Biol Lett 2008; 13: 155-81.